A clinical trial of ABO 101 for Hyperoxaluria
Latest Information Update: 25 Oct 2024
Price :
$35 *
At a glance
- Drugs ABO 101 Arbor Biotechnologies (Primary)
- Indications Hyperoxaluria
- Focus Adverse reactions
- 25 Oct 2024 New trial record
- 30 Sep 2024 According to Arbor Biotechnologies media release, company plans to file an IND/CTA application for Hyperoxaluria by the end of 2024